Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (2): 44-51.doi: 10.6040/j.issn.1671-7554.0.2018.1490

Previous Articles    

Effects of different doses of menopause hormone therapies in perimenopausal women

XU Wenxian1*, WANG Quanmei2*, MA Linjuan1, HUANG Yizhou1, QI Tongyun1, FU Dongxia1, SONG Yang1, LAN Yibing1, LI Chunming1, CHEN Peiqiong1, YING Qian3, ZHOU Jianhong1   

  1. 1. Department of Gynecology, Womens Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, Zhejiang, China;
    2. Department of Obstetrics and Gynecology, The First People’s Hospital of Tonglu, Tonglu 311500, Zhejiang, China;
    3. Journal of Chinese Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China
  • Published:2022-09-27

PDF (PC)

7

Abstract: Objective To compare the effectiveness and safety of different doses of menopause hormone therapies(MHT)in the remission of menopausal symptoms. Methods The clinical data of 450 perimenopausal women who received MHT during 2012 and 2017 were retrospectively analyzed. According to the doses of estradiol valerate, the pa- 山 东 大 学 学 报 (医 学 版)57卷2期 -徐文娴,等.围绝经期应用不同剂量绝经激素治疗的临床观察 \=-tients were divided into 3 groups:group A(standard dose, n=62), group B(low dose, n=322)and group C(ultralow dose, n=66). One treatment cycle lasted for 28 days, during which the continuous sequential regimen was adopted. Before and after treatment, modified Kupperman menopausal index(mKMI)were surveyed, reproductive hormones and glucolipid metabolic indexes were detected, and breast ultrasound was performed. Results Before treatment, there were no significant differences in the general characters and clinical indexes among the 3 groups(all P>0.05). Compared to baseline, the mKMI scores and follicle stimulating hormone(FSH)level significantly decreased, while estradiol level significantly increased after 1, 3 and 6 treatment cycles in all 3 groups(all P<0.001). After 6 treatment cycles, the level of high-density lipoprotein cholesterol(HDL-C)markedly increased in groups B and C, and the levels of low-density lipoprotein cholesterol(LDL-C), fasting blood glucose and fasting insulin significantly decreased in groups A and B(all P<0.01). There were no statistical changes in the thickness of mammary glands, size of mammary nodules and dilatation of ducts in the 3 groups before and after treatment(all P>0.05). Breast distention occurred in 7 cases(11.3%)in group A, 14 cases in group B(4.3%)and 1 case in group C(1.5%), the difference in incidence between groups A and C was significant(P<0.05). Conclusion The standard, low and ultra-low doses of MHT can effectively relieve the menopausal symptoms in perimenopausal women. The standard and low dose are superior to the ultra-low dose in improving glucolipid metabolism. The ultra-low dose has advantages in tolerance. The different doses of MHT has no effects on the mammary glands during the observation period.

Key words: Menopause hormone therapy, Perimenopause period, Low dose, Ultra-low dose, Menopausal symptoms

CLC Number: 

  • R711
[1] 中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南(2018)[J]. 中华妇产科杂志, 2018, 53(11): 729-739.
[2] 郁琦. 绝经学[M]. 北京: 人民卫生出版社, 2013: 303-304.
[3] Liu M, Wang Y, Li X, et al. A health survey of Beijing middle-aged registered nurses during menopause [J]. Maturitas, 2013, 74(1): 84-88.
[4] Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome [J]. Maturitas, 2016, 91: 42-50. doi:10.1016/j.maturitas.2016.05.015.
[5] Lan Y, Huang Y, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in southeast China [J]. Menopause, 2017, 24(10): 1200-1207.
[6] Huang Y, Chatooah N, Qi T, et al. Health-related quality of life and its associated factors in Chinese middle-aged women [J]. Climacteric, 2018, 21(5): 483-490.
[7] Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on womens midlife health and menopause hormone therapy[J]. Climacteric, 2016, 19(2): 109-150.
[8] The NAMS Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the north american menopause society[J]. Menopause, 2017, 24(7): 728-753.
[9] 陈蓉, 魏代敏, 郁琦. 绝经后小剂量激素补充治疗的有效性和安全性[J]. 中国实用妇科与产科杂志, 2011, 27(9):709-712.
[10] Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track[J]. N Engl J Med, 2016, 374(9): 803-806.
[11] Ku SY, Kang JW, Kim H, et al. Regional differences in age at menopause between Korean-Korean and Korean-Chinese[J]. Menopause, 2004, 11(5): 569-574.
[12] 周小丹. 国内外不同种族/民族妇女围绝经期现况研究进展[J]. 中国妇幼保健, 2012, 27(14): 2227-2229.
[13] Haines CJ, Xing SM, Park KH, et al. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause(PAM)study[J]. Maturitas, 2005, 52(3-4): 264-276.
[14] Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial[J]. Climacteric, 2009, 12(4): 319-328.
[15] Stevenson JC, Durand G, Kahler E, et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study [J]. Maturitas, 2010, 67(3): 227-232.
[16] Polisseni AF, Andrade AT, Ribeiro LC, et al. Effects of a continuous-combined regimen of low-dose hormone therapy(oestradiol and norethindrone acetate)and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study[J]. Maturitas, 2013, 74(2): 172-178.
[17] Janssen I, Powell LH, Crawford S, et al. Menopause and the metabolic syndrome: the Study of Womens Health Across the Nation[J]. Arch Intern Med, 2008, 168(14): 1568-1575.
[18] 何柳, 唐迅, 胡永华. 绝经与心血管疾病及相关代谢紊乱的关联[J]. 北京大学学报(医学版), 2016, 48(3): 448-453. HE Liu, TANG Xun, HU Yonghua. Relationship of menopause with cardiovascular disease and related metabolic disorders[J]. Journal of Peking University(Health Sciences), 2016, 48(3): 448-453.
[19] 陈建芳, 万惠卿, 黄艺舟, 等. 更年期女性胆固醇水平调查与影响因素分析[J]. 中华生殖与避孕杂志, 2017, 37(10): 831-836. CHEN Jianfang, WAN Huiqing, HUANG Yizhou, et al. Investigation of serum cholesterol level of women in different menopausal stages and its influencing factors[J]. Chinese Journal of Reproduction and Contraception, 2017, 37(10): 831-836.
[20] Lovre D, Lindsey SH, Mauvais-Jarvis F. Effect of menopausal hormone therapy on components of the metabolic syndrome[J]. Ther Adv Cardiovasc Dis, 2016.pii: 1753944716649358. doi:10.1177/17539447166-49358.
[21] Casanova G, Radavelli S, Lhullier F, et al. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause[J]. Fertil Steril, 2009, 92(2): 605-612.
[22] Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women[J]. Clin Endocrinol, 2004, 60(5): 541-549.
[23] Matsui S, Yasui T, Tani A, et al. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women[J]. Climacteric, 2014, 17(2): 191-196.
[24] Mattsson LA, Ipsen HE, Granqvist CJ, et al. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy [J]. Climacteric, 2015, 18(3): 419-425.
[25] Files JA, Miller VM, Cha SS, et al. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study [J]. J Womens Health, 2014, 23(10): 801-805.
[26] Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease[J]. Arterioscler Thromb Vasc Biol, 2007, 27(2): 266-274.
[27] Stute P, Becker HG, Bitzer J, et al. Ultra-low dose- new approaches in menopausal hormone therapy[J]. Climacteric, 2015, 18(2): 182-186.
[28] Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2015, 100(11):3975-4011. doi:10.1210/jc.2015-2236.
[1] YU Xinxin, GUO Lei, CHENG Zhaoping, DUAN Yanhua, WANG Ximing. Clinical value of flash spiral dual-source CT with low-dose scan for children with superficial vascular anomalies [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 68-74.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd